Qiangqiang Zhao1,2, Xiaoying Sun3,4, Bin Wu5, Yinghui Shang1, Xueyuan Huang1, Hang Dong1, Haiting Liu1, Wansong Chen6, Rong Gui7, Jian Li8. 1. Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China. 2. Department of Hematology, The Qinghai Provincial People's Hospital, Xining, 810007, People's Republic of China. 3. School of Nursing, Medical College, Soochow University, Suzhou, 215006, People's Republic of China. 4. Department of Emergency, The Qinghai Provincial People's Hospital, Xining, 810007, People's Republic of China. 5. Department of Transfusion Medicine, Tongji Medical College, Wuhan Hospital of Traditional Chinese and Western Medicine, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China. 6. College of Chemistry and Chemical Engineering, Central South University, Changsha, 410083, People's Republic of China. 7. Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China. zndxgr@163.com. 8. Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China. lj168301018@csu.edu.cn.
Abstract
BACKGROUND: Non-Hodgkin's lymphoma (NHL) possesses great heterogeneity in cytogenetics, immunophenotype and clinical features, and chemotherapy currently serves as the main treatment modality. Although employing monoclonal antibody targeted drugs has significantly improved its overall efficacy, various patients continue to suffer from drug resistance or recurrence. Chinese medicine has long been used in the treatment of malignant tumors. Therefore, we constructed a low pH value sensitivity drug delivery system based on the cancer cell membrane modified mesoporous silica nanoparticles loaded with traditional Chinese medicine, which can reduce systemic toxicity and improve the therapeutic effect for the targeted drug delivery of tumor cells. RESULTS: Accordingly, this study put forward the construction of a nano-platform based on mesoporous silica nanoparticles (MSNs) loaded with the traditional Chinese medicine isoimperatorin (ISOIM), which was camouflaged by the cancer cell membrane (CCM) called CCM@MSNs-ISOIM. The proposed nano-platform has characteristics of immune escape, anti-phagocytosis, high drug loading rate, low pH value sensitivity, good biocompatibility and active targeting of the tumor site, blocking the lymphoma cell cycle and promoting mitochondrial-mediated apoptosis. CONCLUSIONS: Furthermore, this study provides a theoretical basis in finding novel clinical treatments for lymphoma.
BACKGROUND:Non-Hodgkin's lymphoma (NHL) possesses great heterogeneity in cytogenetics, immunophenotype and clinical features, and chemotherapy currently serves as the main treatment modality. Although employing monoclonal antibody targeted drugs has significantly improved its overall efficacy, various patients continue to suffer from drug resistance or recurrence. Chinese medicine has long been used in the treatment of malignant tumors. Therefore, we constructed a low pH value sensitivity drug delivery system based on the cancer cell membrane modified mesoporous silica nanoparticles loaded with traditional Chinese medicine, which can reduce systemic toxicity and improve the therapeutic effect for the targeted drug delivery of tumor cells. RESULTS: Accordingly, this study put forward the construction of a nano-platform based on mesoporous silica nanoparticles (MSNs) loaded with the traditional Chinese medicine isoimperatorin (ISOIM), which was camouflaged by the cancer cell membrane (CCM) called CCM@MSNs-ISOIM. The proposed nano-platform has characteristics of immune escape, anti-phagocytosis, high drug loading rate, low pH value sensitivity, good biocompatibility and active targeting of the tumor site, blocking the lymphoma cell cycle and promoting mitochondrial-mediated apoptosis. CONCLUSIONS: Furthermore, this study provides a theoretical basis in finding novel clinical treatments for lymphoma.
Entities:
Keywords:
Apoptosis; Cancer cell membrane; Isoimperatorin; Lymphom; Mesoporous silica nanoparticles
Authors: Dai Chihara; Jason R Westin; Yasuhiro Oki; Mohamed A Ahmed; Bryan Do; Luis E Fayad; Fredrick B Hagemeister; Jorge E Romaguera; Michelle A Fanale; Hun J Lee; Francesco Turturro; Felipe Samaniego; Sattva S Neelapu; M Alma Rodriguez; Nathan H Fowler; Michael Wang; Richard E Davis; Loretta J Nastoupil Journal: Cancer Date: 2016-06-28 Impact factor: 6.860
Authors: Enli Liu; David Marin; Pinaki Banerjee; Homer A Macapinlac; Philip Thompson; Rafet Basar; Lucila Nassif Kerbauy; Bethany Overman; Peter Thall; Mecit Kaplan; Vandana Nandivada; Indresh Kaur; Ana Nunez Cortes; Kai Cao; May Daher; Chitra Hosing; Evan N Cohen; Partow Kebriaei; Rohtesh Mehta; Sattva Neelapu; Yago Nieto; Michael Wang; William Wierda; Michael Keating; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani Journal: N Engl J Med Date: 2020-02-06 Impact factor: 91.245